论文部分内容阅读
Objective:To confirm the value of GnRH antagonist(GnRHant) cetrorelix in preventing the occurrence of premature LH surges and compare a multiple dose and a single dose GnRHant protocols for the COS of IVF/ICSI patients with a short GnRHa protocol. Methods:Single-center randomized,prospective,controlled study was conducted in our study.Ninety infertile women who underwent ovarian stimulation for IVF-ET were selected.Multiple dose of 0.25 mg(Group I) and single dose of 3 mg(GroupⅡ)of cetrorelix(60 patients) was administered in the late follicular phase.A depot preparation of triptorelin(Decapeptyl) was chosen as a control agent(30 patients)(GroupⅢ).Ovarian stimulation was conducted with FSH. Results:No premature LH surge occurred after cetrorelix administration.The mean numbers of mature oocytes obtained from patients were(13.47 7.60),(18.66 8.37) and(15.77 10.78) in GroupsⅠ,ⅡandⅢ,respectively, showing no statistical difference.The fertilization rates were(78.97 18.11)%in GroupⅠ,(72.35 25.44)%in GroupⅡand(76.80 23.10)%in GroupⅢ.The clinical pregnancy rates of patients were statistically comparable in the GnRHa group(30.8%) and in the GnRHant group(37.9%in GroupⅠ,28.6%in GroupⅡ),as ongoing pregnancy rates of embryo transfer were 31.0%,25.9%,30.8%for the GroupⅠ,ⅡandⅢ,respectively.The miscarriage rate was not different in the three groups.There were four patients cancelled embryo transfer for preventing severe ovarian hyperstimulation syndrome(OHSS) in triptorelin group,and 1 patient in each cetrorelix group.No severe or moderate OHSS of cetrorelix groups occurred. Conclusion:Both single-dose and multi-dose cetrorelix protocols prevented premature LH surges in all patients studied.GnRHant and GnRHa provide comparable results in patients,while GnRHant allows a higher flexibility in the treatment.
Objective: To confirm the value of GnRH antagonist (GnRHant) cetrorelix in preventing the occurrence of premature LH surges and compare a multiple dose and a single dose GnRHant protocols for the COS of IVF / ICSI patients with a short GnRHa protocol. Methods: Single- center randomized, prospective, controlled study was conducted in our study. Negative infertile women who underwent ovarian stimulation for IVF-ET were selected. Multiple dose of 0.25 mg (Group I) and single dose of 3 mg (Group II) of cetrorelix ) was administered in the late follicular phase. A depot preparation of triptorelin (Decapeptyl) was chosen as a control agent (30 patients) (Group III). Ovarian stimulation was conducted with FSH. Results: No premature LH surge occurred after cetrorelix administration. Mean numbers of mature oocytes were obtained from patients were (13.47 7.60), (18.66 8.37) and (15.77 10.78) in Groups I, II and III, respectively, showing no statistical difference. The fertilization rates were (78.97 18.11)% in Group The clinical pregnancy rates of patients were statistically comparable in the GnRHa group (30.8%) and in the GnRHant group (37.9% in Group I, 28.6% in Group II) (72. 35 25.44)% in Group II and , as as compared to embryo transfer rates 31.0%, 25.9%, 30.8% for the Group I, II and III, respectively. The miscarriage rate was not different in the three groups. There were four patients canceled embryo transfer for preventing severe ovarian hyperstimulation syndrome ( OHSS) in triptorelin group, and 1 patient in each cetrorelix group. No severe or moderate OHSS of cetrorelix groups occurred. Conclusion: Both single-dose and multi-dose cetrorelix protocols prevented premature LH surges in all patients studied. GnRHant and GnRHa provide comparable results in patients, while GnRHant allows a higher flexibility in the treatment.